Royal Bank of Canada
INBX icon

Royal Bank of Canada’s Inhibrx INBX Stock Holding History

Royal Bank of Canada’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7K Sell
107
-250
-70% -$18.5K ﹤0.01% 6318
2025
Q4 		$29K Sell
357
-109
-23% -$7.43K ﹤0.01% 5844
2025
Q3 		$16K Sell
466
-929
-67% -$22.9K ﹤0.01% 6307
2025
Q2 		$20K Buy
1,395
+1,076
+337% +$13.9K ﹤0.01% 6266
2025
Q1 		$4K Sell
319
-1,007
-76% -$13.7K ﹤0.01% 6408
2024
Q4 		$21K Sell
1,326
-556
-30% -$8.47K ﹤0.01% 6086
2024
Q3 		$29K Buy
1,882
+801
+74% +$11.3K ﹤0.01% 5953
2024
Q2 		$15K Buy
+1,081
New +$16.9K ﹤0.01% 6183

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Royal Bank of Canada's INBX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Inhibrx (INBX) stake by 70% in Q1 2026, selling an estimated $18.5K and leaving 107 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #6318.

Royal Bank of Canada first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. The position peaked at $29K in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Royal Bank of Canada held 107 shares of Inhibrx worth $7K as of Q1 2026.
  • Royal Bank of Canada sold 250 Inhibrx shares in Q1 2026, an estimated $18.5K.
  • Inhibrx made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6318 holding.
  • Royal Bank of Canada first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
  • Royal Bank of Canada's Inhibrx position peaked at $29K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.